Targeting casein kinase 1 for cancer therapy: current strategies and future perspectives

Ngo Hoang Long; Sook-Jeong Lee

doi:10.3389/fonc.2023.1244775

Targeting casein kinase 1 for cancer therapy: current strategies and future perspectives

Front Oncol. 2023 Nov 8:13:1244775. doi: 10.3389/fonc.2023.1244775. eCollection 2023.

Authors

Ngo Hoang Long¹, Sook-Jeong Lee¹

Affiliation

¹ Department of Bioactive Material Sciences, Jeonbuk National University, Jeonju, Jeollabuk-do, Republic of Korea.

Abstract

Casein Kinase 1 (CK1) is a family of serine/threonine protein kinases that play a crucial role in various cellular processes, including cell proliferation, survival, and metabolism. The dysregulation of CK1 expression has been implicated in the development and progression of several types of cancer, making it an attractive target for anticancer therapy. In this review, we provide an overview of the current strategies employed to target CK1 for cancer therapy and discuss the future perspectives in this field. We highlight the different approaches, including small molecule inhibitors, RNA interference, genome editing, and immunotherapies, which hold immense potential for targeted modulation of CK1 activity in cancer cells. Furthermore, we discuss the challenges associated with targeting CK1 and propose potential strategies to overcome these hurdles. Overall, targeting CK1 holds great promise as a therapeutic strategy for cancer treatment, and further research in this area is warranted.

Keywords: RNA interference; cancer therapy; casein kinase 1; clinical strategy; gene targeting; immunotherapy.

Publication types

Review

Grants and funding

This work was supported by a National Research Foundation (NRF) grant funded by the Korean government (MSIT) (No. NRF-2021R1A2C1005980). This study was also supported by Jeonbuk National University, Republic of Korea. Mr. Long Ngo Hoang was supported by the Brain Korea 21 program at the Department of Bioactive Material Sciences.